Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 + Imatinib in Refractory GIST
NCT01275222Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2002
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of everolimus in gastrointestinal stromal tumor (GIST) (6 arms), sponsored by Novartis. Primary endpoints: Number of Participants With Adverse Events, Best Overall Response and 4 more. Started Nov 2002; status: completed.
02
Drugs
everolimus
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01275222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275222.